News from amgen inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 25, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of...

Nov 24, 2014, 09:15 ET
Amgen Logo.

Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer

 Amgen (NASDAQ:AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer,...

Nov 18, 2014, 16:00 ET
Amgen Logo.

Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels

Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational...

Nov 14, 2014, 16:15 ET
Amgen Logo.

Amgen To Present At The Jefferies Global Healthcare Conference

Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m....

Nov 12, 2014, 16:35 ET
Amgen Logo.

Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on...

Nov 12, 2014, 16:01 ET
Amgen Logo

Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab

Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014...

Nov 12, 2014, 09:00 ET
Amgen Scholars Program Expands To 17 Top Educational Institutions Worldwide

The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide

 The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe,...

Nov 11, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of...

Nov 10, 2014, 09:15 ET
Amgen Logo.

FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application...

Nov 06, 2014, 16:30 ET
Amgen Logo.

Amgen To Present At The Credit Suisse Annual Healthcare Conference

 Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov. 11, 2014, at The Arizona Biltmore in...

Nov 06, 2014, 16:01 ET
Amgen Logo.

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014

 Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's...

Nov 04, 2014, 09:00 ET
Amgen Logo.

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

 Amgen (NASDAQ:AMGN) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with...

Oct 28, 2014, 08:48 ET
Amgen Logo

Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans

Amgen (NASDAQ:AMGN) today outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for...

Oct 27, 2014, 16:01 ET
Amgen Logo.

Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30

 Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2014. Key results include: - Total revenues increased...

Oct 23, 2014, 17:39 ET
Amgen Logo.

Amgen To Webcast 2014 Business Review Meeting On October 28

Amgen (NASDAQ: AMGN) today announced that it will hold its Business Review Meeting on Tuesday, Oct. 28, 2014, at the Conrad New York, 102 North End...

Oct 23, 2014, 16:05 ET
Amgen Logo.

Amgen Announces Webcast of 2014 Third Quarter Financial Results

Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Monday, Oct. 27, 2014, after the close of the U.S....

Oct 21, 2014, 15:41 ET
Amgen Logo.

Amgen Statement Regarding Third Point Investment

Amgen (NASDAQ: AMGN) issued the following statement with respect to media inquiries concerning Third Point LLC's equity position in Amgen: Amgen...

Oct 17, 2014, 16:17 ET
Amgen Logo.

Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors

 Amgen (NASDAQ: AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W....

Oct 17, 2014, 16:03 ET
Amgen Logo.

Amgen Announces 2014 Fourth Quarter Dividend

Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the fourth quarter of 2014. The dividend...

Oct 17, 2014, 09:00 ET
Amgen Logo.

Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement

Amgen (NASDAQ: AMGN) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC,...